| 2024-04-03 20:43 | CC:NGEN | Nervgen Pharma Corp | 2.34 | Prospectus Approved3 | Nervgen Pharma prospectus offering |
| 2024-03-28 13:21 | CC:NGEN | Nervgen Pharma Corp | 2.18 | News Release200 | Nervgen Pharma closes $23.01-million bought deal |
| 2024-03-22 07:38 | CC:NGEN | Nervgen Pharma Corp | 2.49 | Resume Trading385 | Nervgen Pharma resuming at the open |
| 2024-03-21 16:12 | CC:NGEN | Nervgen Pharma Corp | 2.49 | News Release200 | Nervgen Pharma arranges $20-million offering |
| 2024-03-21 15:51 | CC:NGEN | Nervgen Pharma Corp | 2.55 | Halt Trading170 | Nervgen Pharma halted at 12:43 p.m. PT |
| 2024-02-20 17:47 | CC:NGEN | Nervgen Pharma Corp | 3.32 | News Release200 | Nervgen grants options to buy shares |
| 2024-02-15 13:06 | CC:NGEN | Nervgen Pharma Corp | 3.01 | News Release200 | Nervgen to complete NVG-291 enrolment in Q2 2024 |
| 2023-11-09 14:25 | CC:NGEN | Nervgen Pharma Corp | 1.96 | News Release200 | Nervgen Pharma's Sept. 30 cash at $14.8-million |
| 2023-11-09 10:12 | CC:NGEN | Nervgen Pharma Corp | 1.96 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-11-09 10:12 | CC:NGEN | Nervgen Pharma Corp | 1.96 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2023-10-23 11:30 | CC:NGEN | Nervgen Pharma Corp | 1.79 | News Release200 | Nervgen receives fast-track designation for NVG-291 |
| 2023-10-17 13:01 | CC:NGEN | Nervgen Pharma Corp | 1.75 | News Release200 | Nervgen appoints Ruffolo as director |
| 2023-09-25 09:56 | CC:NGEN | Nervgen Pharma Corp | 2.05 | News Release200 | Nervgen doses first patient in spinal cord injury trial |
| 2023-08-09 15:25 | CC:NGEN | Nervgen Pharma Corp | 1.85 | News Release200 | Nervgen cash and investments at $16.1M at June 30 |
| 2023-08-09 08:28 | CC:NGEN | Nervgen Pharma Corp | 1.85 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-08-08 11:44 | CC:NGEN | Nervgen Pharma Corp | 1.85 | News Release200 | Nervgen receives IRB OK for NVG-291 trial |
| 2023-06-27 11:11 | CC:NGEN | Nervgen Pharma Corp | 1.71 | News Release200 | Nervgen receives $3.18M (U.S.) grant for NVG-291 trial |
| 2023-06-02 18:20 | CC:NGEN | Nervgen Pharma Corp | 1.70 | News Release200 | Nervgen Pharma extends option expiry by two years |
| 2023-05-23 17:34 | CC:NGEN | Nervgen Pharma Corp | 1.65 | News Release200 | Nervgen grants options to buy 400,000 shares |
| 2023-05-18 19:15 | CC:NGEN | Nervgen Pharma Corp | 1.61 | News Release200 | Nervgen shareholders re-elect nine directors at AGM |
| 2023-05-15 14:43 | CC:NGEN | Nervgen Pharma Corp | 1.60 | News Release200 | Nervgen Pharma spends $3M on R&D in Q1 2023 |
| 2023-05-15 08:05 | CC:NGEN | Nervgen Pharma Corp | 1.60 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-05-15 08:05 | CC:NGEN | Nervgen Pharma Corp | 1.60 | SEDAR MD & A815 | SEDAR MD & A |
| 2023-04-28 16:11 | CC:NGEN | Nervgen Pharma Corp | 1.66 | SEDAR Annual Information Form802 | SEDAR Annual Information Form |
| 2023-04-18 20:04 | CC:NGEN | Nervgen Pharma Corp | 1.72 | Shares for Debt330 | Nervgen Pharma 590,000 shares for services |